Prognostic factors in multiple myeloma

Hematology/Oncology Clinics of North America

Volumn 13, Issue 6, 1999, Pages 1295-1314

  Rajkumar, S Vincent ^b   Greipp, Philip R ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CARMUSTINE; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; HUMAN; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

EID: 0033400218     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70128-3     Document Type: Article

References (138)

1. G.J. Ahmann S.M. Jalal A.L. Juneau A novel three-color, clone-specific FISH procedure for monoclonal gammopathies [abstract] Blood 88 suppl 1 1996 387a
2. G.J. Ahmann S.M. Jalal A.L. Juneau A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies Cancer Genet Cytogenet 101 1998 7
3. R. Alexanian M. Dimopoulos The treatment of multiple myeloma N Engl J Med 330 1994 484
4. 12 proteins in multiple myeloma J Med 21 1990 277
5. M. Attal J.L. Harousseau A.M. Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 1996 91
6. B. Barlogie R. Alexanian D. Dixon Prognostic implications of tumor cell DNA and RNA content in multiple myeloma Blood 66 1985 338
7. B. Barlogie S. Jagannath K.R. Desikan Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 1999 55
8. B. Barlogie S. Jagannath J. Epstein Biology and therapy of multiple myeloma in 1996 Semin Hematol 34 1997 67
9. B. Barlogie L. Smallwood T. Smith High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma Ann Intern Med 110 1989 521
10. R. Bartl B. Frisch R. Burkhardt Bone marrow histology in myeloma: Its importance in diagnosis, prognosis, classification and staging Br J Haematol 51 1982 361
11. R. Bataille M. Boccadoro B. Klein C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system Blood 80 1992 733
12. R. Bataille B.G. Durie J. Grenier Serum beta-2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging Br J Haematol 55 1983 439
13. R. Bataille J.L. Harousseau Multiple myeloma N Engl J Med 336 1997 1657
14. R. Bataille M. Jourdan X.G. Zhang Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias J Clin Invest 84 1989 2008
15. R. Bataille C. Vincent J.P. Revillard Serum beta-2-microglobulin binding activity in monoclonal gammopathy: Correlative study and clinical significance European Journal of Cancer and Clinical Oncology 19 1983 1075
16. P.L. Bergsagel M. Chesi E. Nardini Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma Proc Natl Acad Sci U S A 93 1996 13931
17. P.L. Bergsagel E. Nardini L. Brents IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc Curr Topics Microbiol Immunol 224 1997 283
18. J. Bladé R.A. Kyle P.R. Greipp Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years Br J Haematol 93 1996 345
19. M. Boccadoro S. Battaglio P. Omede Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma Eur J Haematol 47 1991 305
20. M. Boccadoro F. Marmont M. Tribalto Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis J Clin Oncol 7 1989 119
21. M. Boccadoro F. Marmont M. Tribalto Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients J Clin Oncol 9 1991 444
22. D.G. Bostwick T.M. Wheeler M. Blute Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies Urology 48 1996 47
23. C. Brigaudeau F. Trimoreau N. Gachard Cytogenetic study of 30 patients with multiple myeloma: Comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method Br J Haematol 96 1997 594
24. R.D. Brown D.E. Joshua R.A. Ioannidis Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma Aust N Z J Med 19 1989 226
25. A. Carter I. Hocherman S. Linn Prognostic significance of plasma cell morphology in multiple myeloma Cancer 60 1987 1060
26. G. Cimino G. Avvisati S. Amadori High serum IL-2 levels are predictive of prolonged survival in multiple myeloma Br J Haematol 75 1990 373
27. J.J. Cornelissen P. Sonneveld M. Schoester MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents J Clin Oncol 12 1994 115
28. J. Cuzick B.L. De Stavola E.H. Cooper Long-term prognostic value of serum beta 2 microglobulin in myelomatosis Br J Haematol 75 1990 506
29. G.W. Dewald R.A. Kyle G.A. Hicks The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis Blood 66 1985 380
30. A.J. Dickinson S.B. Fox R.A. Persad Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas Br J Urol 74 1994 762
31. M.A. Dimopoulos B. Barlogie T.L. Smith High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma Ann Intern Med 115 1991 931
32. M.A. Dimopoulos A. Moulopoulos T. Smith Risk of disease progression in asymptomatic multiple myeloma Am J Med 94 1993 57
33. K.A. Donovan M.Q. Lacy M.P. Kline Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma Leukemia 12 1998 593
34. J. Drach J. Ackermann E. Fritz Presence of a P53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy Blood 92 1998 802
35. J. Drach J. Angerler J. Schuster Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance Blood 86 1995 3915
36. J. Drach C. Gattringer H. Glassl The biological and clinical significance of the KI-67 growth fraction in multiple myeloma Hematol Oncol 10 1992 125
37. J. Drach J. Schuster H. Nowotny Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization Cancer Res 55 1995 3854
38. B.G. Durie T.M. Grogan CALLA-positive myeloma: An aggressive subtype with poor survival Blood 66 1985 229
39. B.G. Durie S.E. Salmon A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 1975 842
40. B.G. Durie S.E. Salmon T.E. Moon Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma Blood 55 1980 364
41. I. Elomaa P. Virkkunen L. Risteli Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma Br J Cancer 66 1992 337
42. J. Epstein H.Q. Xiao X.Y. He Markers of multiple hematopoietic-cell lineages in multiple myeloma N Engl J Med 322 1990 664
43. J. Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182
44. J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N Engl J Med 333 1995 1757
45. J. Folkman New perspectives in clinical oncology from angiogenesis research Eur J Cancer 14 1996 2534
46. R. Fonseca G.J. Ahmann A.L. Juneau Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders: A comparison of conventional cytogenetics to fluorescent in situ hybridization with simultaneous cytoplasmic immunoglobulin staining [abstract] Blood 90 suppl 1 1997 349a
47. S.B. Fox Tumour angiogenesis and prognosis Histopathology 30 1997 294
48. S.B. Fox R.D. Leek M.P. Weekes Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis J Pathol 177 1995 275
49. J.P. Gaillard R. Bataille H. Brailly Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy Eur J Immunol 23 1993 820
50. J.P. Gaillard J. Liautard B. Klein Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines Eur J Immunol 27 1997 3332
51. H. Garewal B.G. Durie R.A. Kyle Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders J Clin Oncol 2 1984 51
52. M.A. Gertz A.A. Pineda M.G. Chen Refractory and relapsing multiple myeloma treated by blood stem cell transplantation Am J Med Sci 309 1995 152
53. M. Girino A. Riccardi R. Luoni Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies Acta Haematol 85 1991 26
54. P.R. Greipp Prognosis in myeloma Mayo Clin Proc 69 1994 895
55. P.R. Greipp J.P. Gaillard L.A. Kalish Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487 [abstract] Proceedings of the Annual Meeting of the American Society of Clinical Oncology 12 1993 404
56. 2M), soluble interleukin-6 receptor (sIL-6R), and C-reactive protein (CRP) in myeloma trial E9487 (abstract) Blood 84 suppl 1 1994 385a
57. P.R. Greipp J.A. Katzmann W.M. O'Fallon Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma Blood 72 1988 219
58. P.R. Greipp T. Leong J.M. Bennett Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 report by the ECOG Myeloma Laboratory Group Blood 91 1998 2501
59. P.R. Greipp T. Leong N.E. Kay From ECOG myeloma trial E9486: A prognostic index based on tumor burden, proliferation and host immune status [abstract] Blood 90 suppl 1 1997 350a
60. P.R. Greipp J.A. Lust W.M. O'Fallon Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 81 1993 3382
61. 2M) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487 [abstract] Proceedings of the Annual Meeting of the American Society of Clinical Oncology 11 1992 357
62. P.R. Greipp N.M. Raymond R.A. Kyle Multiple myeloma: Significance of plasmablastic subtype in morphological classification Blood 65 1985 305
63. P.R. Greipp T.E. Witzig M.A. Gertz Clinical application of cell kinetics to patients with monoclonal gammopathy and multiple myeloma Cell and Tissue Kinetics 23 1990 348
64. P.R. Greipp T.E. Witzig N.J. Gonchoroff Immunofluorescent plasma cell labeling indices (Li) using a monoclonal antibody (Bu-1) Am J Hematol 20 1985 289
65. M.S. Hamilton J. Ball E. Bromidge Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion Br J Haematol 78 1991 60
66. J.L. Harousseau M. Attal The role of autologous hematopoietic stem cell transplantation in multiple myeloma Semin Hematol 34 suppl 1 1997 61
67. K. Ide G.J. Ahmann P.C. Roche Evaluation of a PCNA labeling index in multiple myeloma (MM) [abstract] Blood 80 1992 486a
68. J.A. Katzmann P.R. Greipp W.F. O'Fallon Serum beta 2-microglobulin Mayo Clin Proc 61 1986 752
69. N.E. Kay T. Leong R.A. Kyle Circulating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial Blood 90 1997 340
70. T. Kishimoto The biology of interleukin-6 Blood 74 1989 1
71. B. Klein X.G. Zhang Z.Y. Lu Interleukin-6 in human multiple myeloma Blood 85 1995 863
72. T.J. Kovacsovics A. Delaly Intensive treatment strategies in myeloma Semin Hematol 34 1997 49
73. H. Kurabayashi K. Kubota T. Shirakura Electron microscopic analysis of myeloma cells in relation to drug response and prognosis Ultrastruct Pathol 16 1992 379
74. R.A. Kyle Long-term survival in multiple myeloma N Engl J Med 308 1983 314
75. R.A. Kyle Prognostic factors in multiple myeloma Stem Cells 2 1995 56
76. J.L. Lai M. Zandecki J.Y. Mary Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis Blood 85 1995 2490
77. S.H. Landis T. Murray S. Bolden Cancer statistics, 1999 CA Cancer J Clin 49 1999 8
78. J. Latreille B. Barlogie D. Johnston Ploidy and proliferative characteristics in monoclonal gammopathies Blood 59 1982 43
79. R. Leo M. Boeker D. Peest Multiparameter analyses of normal and malignant human plasma cells: Cd38++, Cd56+, Cd54+, Cig+ is the common phenotype of myeloma cells Ann Hematol 64 1992 132
80. P. Liu T. Leong L. Quam Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial Blood 88 1996 2699
81. J.A. Lust K.A. Donovan Biology and transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma Cancer Control 5 1998 209
82. J.A. Lust K.A. Donovan M.P. Kline Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor Cytokine 4 1992 96
83. I.C.M. MacLennan D.L. Hardie J. Ball Antibody-secreting cells and their origins J.S. Malpas D.E. Bergsagel R.A. Kyle Myeloma: Biology and Management 1995 Oxford University Press Oxford 30
84. S. Matozaki T. Nakagawa Y. Nakao RAS gene mutations in multiple myeloma and related monoclonal gammopathies Kobe J Med Sci 37 1991 35
85. Medical Research Council's Working Party on Leukaemia in Adults Prognostic features in the third MRC myelomatosis trial Br J Cancer 42 1980 831
86. G. Merlini V. Perfetti P.G. Gobbi Acute phase proteins and prognosis in multiple myeloma Br J Haematol 83 1993 595
87. G. Merlini J.G. Waldenstrom S.D. Jayakar A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients Blood 55 1980 1011
88. C. Montecucco A. Riccardi G. Ucci Analysis of human myeloma cell population kinetics Acta Haematol (Basel) 75 1986 153
89. N. Munshi C.S. Wilson J. Penn Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies [abstract] Blood 92 1998 98a
90. N.C. Munshi C.S. Wilson J. Penn Bone marrow neo-angiogenesis in multiple myeloma predicts poor prognosis [abstract] Proceedings of the Annual Meeting of the American Society of Clinical Oncology 18 1999 18a
91. H. Murakami K. Nemoto M. Sawamura Prognostic relevance of morphological classification in multiple myeloma Acta Haematol 87 1992 113
92. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 1998 3832
93. D.M. Nachbaur M. Herold A. Maneschg Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters Ann Hematol 62 1991 54
94. A. Neri L. Baldini D. Trecca p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood 81 1993 128
95. A. Neri J.P. Murphy L. Cro Ras oncogene mutation in multiple myeloma J Exp Med 170 1989 1715
96. K. Nishida A. Tamura N. Nakazawa The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization Blood 90 1997 526
97. M.M. Oken D.P. Harrington N. Abramson Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479 Cancer 79 1997 1561
98. K. Oritani S. Katagiri N. Tominaga Aberrant expression of immunoglobulin light chain isotype in B lymphocytes from patients with monoclonal gammopathies: Isotypic discordance and clonal B-cell excess Br J Haematol 75 1990 10
99. B. Paule J. Quillard P. Bennet Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: A study of 35 serial bone marrow biopsies in 9 patients Nouvelle Revue Française D'Hématologie 31 1989 203
100. B. Paule J. Quillard M. Bisson Prognostic significance of plasma cell morphology in multiple myeloma Nouvelle Revue Française D'Hématologie 30 1988 209
101. A. Pich F. Marmont L. Chiusa Argyrophilic nucleolar organizer region counts and prognosis in multiple myeloma Br J Haematol 82 1992 681
102. S.V. Rajkumar R. Fonseca S.M. Ansell Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma [abstract] Blood 92 suppl 1 1998 100A
103. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet, in press
104. S.V. Rajkumar R. Fonseca M.Q. Lacy Abnormal cytogenetics predict for poor survival after peripheral stem cell transplantation in relapsed multiple myeloma [abstract] Blood 90 suppl 1 1997 527a
105. Rajkumar SV, Fonseca R, Lacy MQ, et al. Abnormal cytogenetics predict poor survival in patients undergoing high dose chemotherapy with peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant, in press
106. S.V. Rajkumar R. Fonseca M.Q. Lacy Beta 2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma Bone Marrow Transplant 23 1999 1261
107. S.V. Rajkumar R. Fonseca M.Q. Lacy Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma J Clin Oncol 17 1999 1551
108. S.V. Rajkumar R. Fonseca T.E. Witzig Bone marrow angiogenesis in complete responders after stem cell transplantation for multiple myeloma Leukemia 13 1999 469
109. S.V. Rajkumar T. Leong R. Fonseca Prognostic value of bone marrow angiogenesis in myeloma. An Eastern Cooperative Oncology Group Study Proceedings of the American Society of Clinical Oncology 18 1999 19a
110. B.L. Rapoport H.C. Falkson G. Falkson Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients S Afr Med J 79 1991 65
111. G.J. Ruiz-Arguelles J.F. San Miguel Cell surface markers in multiple myeloma Mayo Clin Proc 69 1994 684
112. S.M. Saeed N.D. Stock R. Pohlod Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: A Southwest Oncology Group study Blood 78 1991 3281
113. J.F. San Miguel R. García-Sanz M. Gonzalez A new staging system for multiple myeloma based on the number of S-phase plasma cells Blood 85 1995 448
114. J.F. San Miguel R. García-Sanz M. Gonzalez Immunophenotype and DNA cell content in multiple myeloma Baillieres Clin Haematol 8 1995 735
115. J.F. San Miguel M. González A. Gascón Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Br J Haematol 77 1991 185
116. J.F. San Miguel M. González A. Gascón Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies Br J Haematol 80 1992 305
117. J.F. San Miguel J. Sanchez M. González Prognostic factors and classification in multiple myeloma Br J Cancer 59 1989 113
118. J.R. Sawyer J.A. Waldron S. Jagannath Cytogenetic findings in 200 patients with multiple myeloma Cancer Genet Cytogenet 82 1995 41
119. C. Seidel M. Borset I. Turesson Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group Blood 91 1998 806
120. D.S. Siegel K.R. Desikan J. Mehta Age is not a prognostic variable with autotransplants for multiple myeloma Blood 93 1999 51
121. D.R. Simpson L.C. Berkahn J. Squire Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT) [abstract] Blood 90 suppl 1 1997 527a
122. E. Solary M. Guiguet V. Zeller Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma Am J Hematol 39 1992 163
123. R. Stauder M. Van Driel C. Schwarzler Different CD44 splicing patterns define prognostic subgroups in multiple myeloma Blood 88 1996 3101
124. M.C. Trendle P.R. Greipp T. Leong Prognostic significance of the S-phase fraction of light chain restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma (abstract) Proceedings of the Annual Meeting of the American Society of Clinical Oncology 15 1996 446
125. M.C. Trendle T. Leong R.A. Kyle Hypodiploid myeloma revisited: Response to therapy and survival in Eastern Cooperative Oncology Group Study E9486 [abstract] Blood 88 suppl 1 1996 390a
126. M.C. Trendle T. Leong R.A. Kyle Measurements of serum markers of bone metabolism in patients with newly diagnosed multiple myeloma: A study from the ECOG myeloma clinical trials group [abstract] Proc Annu Meet Am Assoc Cancer Res 38 1997 22
127. G. Tricot J.R. Sawyer S. Jagannath Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants J Clin Oncol 15 1997 2659
128. A. Vacca D. Ribatti L. Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503
129. A. Vacca D. Ribatti L. Roncali Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies Leuk Lymphoma 20 1995 27
130. J. Waldron R. Jazieh S. Jagannath Bone marrow morphology (BMM) adds critical prognostic information to other standard parameters (SP) including cytogenetics among newly diagnosed multiple myeloma (MM) patients (PTS) receiving total therapy (TT) [abstract] Blood 90 suppl 1 1997 90a
131. N. Weidner J.P. Semple W.R. Welch Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma N Engl J Med 324 1991 1
132. T.E. Witzig Detection of malignant cells in the peripheral blood of patients with multiple myeloma: Clinical implications and research applications Mayo Clin Proc 69 1994 903
133. T.E. Witzig M.V. Dhodapkar R.A. Kyle Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma Cancer 72 1993 108
134. T.E. Witzig M.A. Gertz J.A. Lust Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma Blood 88 1996 1780
135. T.E. Witzig N.J. Gonchoroff J.A. Katzmann Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies J Clin Oncol 6 1988 1041
136. T.E. Witzig R.A. Kyle W.M. O'Fallon Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma Br J Haematol 87 1994 266
137. M. Zandecki Multiple myeloma—Almost all patients are cytogenetically abnormal Br J Haematol 94 1996 217
138. X.G. Zhang B. Klein R. Bataille Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma Blood 74 1989 11